Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Labetalol: an alpha- and beta-blocker.

C S Conner

    Drug Intelligence & Clinical Pharmacy
    |July 1, 1983
    PubMed
    Summary

    Labetalol, an alpha- and beta-blocker, effectively treats hypertension with minimal cardiac impact. It offers advantages over propranolol for patients with coronary artery disease and is safe for those with obstructive airway diseases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Withered Yang: a review of traditional Chinese medical treatment of male infertility and erectile dysfunction.

    Journal of andrology·2001
    Same author

    Conflicting data in the literature: a true dilemma.

    Drug intelligence & clinical pharmacy·1986
    Same author

    beta-Lactamase inhibitors.

    Drug intelligence & clinical pharmacy·1985
    Same author

    Transdermal nitroglycerin: a reevaluation.

    Drug intelligence & clinical pharmacy·1984
    Same author

    Oral gold in arthritis.

    Drug intelligence & clinical pharmacy·1984
    Same author

    Atracurium and vecuronium: two unique neuromuscular blocking agents.

    Drug intelligence & clinical pharmacy·1984

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine

    Background:

    • Labetalol is an alpha- and beta-adrenoreceptor antagonist.
    • It exhibits a beta:alpha blockade ratio of approximately 7:1.

    Purpose of the Study:

    • To evaluate the efficacy and safety of labetalol in treating hypertension.
    • To compare labetalol's effects with propranolol, particularly in patients with coronary artery disease.

    Main Methods:

    • Labetalol administered intravenously or orally.
    • Evaluation of antihypertensive effects, cardiac output, and left ventricular function at rest and during exercise.

    Main Results:

    • Labetalol demonstrates effective hypertension treatment with minimal impact on cardiac output.
    • It shows more potent antihypertensive effects and less impact on left ventricular function compared to propranolol.
    • The drug is safe in obstructive airway diseases.

    Conclusions:

    • Labetalol offers advantages over propranolol in managing hypertension, especially in patients with coronary artery disease.
    • It is a viable option for patients unresponsive to other beta-blockers or when beta-blockers are contraindicated.
    • Labetalol provides benefits for long-term treatment post-myocardial infarction and in patients with congestive heart failure.

    Related Experiment Videos